Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Lotem

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Anticancer Research|December 6, 2015
Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100βVivian Barak, Vera Leibovici, Tamar Peretz, et al.
American Journal of Ophthalmology|January 31, 2026
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanomaDaniela Vaisman, Jacob Pe'er, Maya Eiger-Moscovich, et al.
Immunotherapy|January 28, 2017
Adoptive cell therapy: past, present and futureJonathan E Cohen, Sharon Merims, Stephen Frank, et al.
Molecular Cancer Research : MCR|March 22, 2007
Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progressionZaidoun Salah, Myriam Maoz, Elisheva Pokroy, et al.
American Journal of Ophthalmology|May 11, 2026
Reply to comments on Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanomaDaniela Vaisman, Jacob Pe'er, Maya Eiger-Moscovich, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2021
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanomaMordechai Avner, Marina Orevi, Nadia Caplan, et al.
Cancer Genetics and Cytogenetics|April 18, 2003
Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell culturesMichal Lotem, Orly Yehuda-Gafni, Eliza Butnaryu, et al.
Oncology|March 24, 2012
The clinical effect of the inhibitor of apopotosis protein livin in melanomaItay Lazar, Riki Perlman, Michal Lotem, et al.
Vaccines|April 23, 2022
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor TherapiesDaniel Ronen, Aseel Bsoul, Michal Lotem, et al.
Familial Cancer|August 6, 2008
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi originLuna Kadouri, Mark Temper, Tal Grenader, et al.
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Anticancer Research|December 6, 2015
Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100βVivian Barak, Vera Leibovici, Tamar Peretz, et al.
American Journal of Ophthalmology|January 31, 2026
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanomaDaniela Vaisman, Jacob Pe'er, Maya Eiger-Moscovich, et al.
Immunotherapy|January 28, 2017
Adoptive cell therapy: past, present and futureJonathan E Cohen, Sharon Merims, Stephen Frank, et al.
Molecular Cancer Research : MCR|March 22, 2007
Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progressionZaidoun Salah, Myriam Maoz, Elisheva Pokroy, et al.
American Journal of Ophthalmology|May 11, 2026
Reply to comments on Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanomaDaniela Vaisman, Jacob Pe'er, Maya Eiger-Moscovich, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2021
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanomaMordechai Avner, Marina Orevi, Nadia Caplan, et al.
Cancer Genetics and Cytogenetics|April 18, 2003
Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell culturesMichal Lotem, Orly Yehuda-Gafni, Eliza Butnaryu, et al.
Oncology|March 24, 2012
The clinical effect of the inhibitor of apopotosis protein livin in melanomaItay Lazar, Riki Perlman, Michal Lotem, et al.
Vaccines|April 23, 2022
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor TherapiesDaniel Ronen, Aseel Bsoul, Michal Lotem, et al.
Familial Cancer|August 6, 2008
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi originLuna Kadouri, Mark Temper, Tal Grenader, et al.
Pageof 10